Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. Wesley H Self , Matthew S Shotwell , Kevin W Gibbs , Marjolein de Wit , D Clark Files , Michelle Harkins , Kristin M Hudock , Lisa H Merck , Ari Moskowitz , Krystle D Apodaca , Aaron Barksdale , Basmah Safdar , Ali Javaheri , Jeffrey M Sturek , Harry Schrager , Nicole Iovine , Brian Tiffany , Ivor S Douglas , Joseph Levitt , Laurence W Busse , Adit A Ginde , Samuel M Brown , David N Hager , Katherine Boyle , Abhijit Duggal , Akram Khan , Michael Lanspa , Peter Chen , Michael Puskarich , Derek Vonderhaar , Lokesh Venkateshaiah , Nina Gentile , Yves Rosenberg , James Troendle , Amanda J Bistran-Hall , Josh DeClercq , Robert Lavieri , Meghan Morrison Joly , Michael Orr , Jill Pulley , Todd W Rice , Jonathan S Schildcrout , Matthew W Semler , Li Wang , Gordon R Bernard , Sean P Collins JAMA(2023)
Abstract
ClinicalTrials.gov Identifier: NCT04924660.
More Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper